stockrow
Friday 6 November 2026
Export PHVS’s income statement to Excel — free account
Pharvaris N.V.
PHVS Healthcare Biotechnology
- EPS
- +13.8%
- Free cash flow
- −17.3%
- Total debt
- +4.31%
Quarter to June 2026, against a year earlier
35.00
2.47
+7.59%
Follow PHVS
Alert me
Pharvaris N.V. (PHVS) EPS (diluted)
Pharvaris N.V.'s EPS (diluted) for fiscal 2025 was −$3.36, compared with −$2.68 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$3.05. Over the past ten years it has ranged from −$6.12 (fiscal 2020) to −$1.05 (fiscal 2018); the current reading is higher than 25% of that period. Pharvaris N.V. ranks 376th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$3.36 | — |
| FY2024 | −$2.68 | — |
| FY2023 | −$2.84 | — |
| FY2022 | −$2.39 | — |
| FY2021 | −$1.66 | — |
| FY2020 | −$6.12 | — |
| FY2019 | −$1.85 | — |
| FY2018 | −$1.05 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$0.81 | — |
| Mar 2026 | −$0.70 | — |
| Dec 2025 | −$0.84 | — |
| Sep 2025 | −$0.70 | — |
| 19 more quarters | Free account |
Against its own ten years
Low −$6.12
High −$1.05
Ten-year median
−$2.54
Current reading's percentile
25
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ADMA ADMA Biologics Inc compare | $0.77 |
| VCEL Vericel Corporation compare | $0.65 |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$0.90 |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$1.69 |
| IMNM Immunome, Inc. compare | −$2.53 |
| PHVS Pharvaris N.V. | −$3.05 |
| BHVN Biohaven Ltd. compare | −$3.86 |
| CLDX Celldex Therapeutics, Inc. compare | −$4.35 |
| PVLA Palvella Therapeutics, Inc. compare | −$4.83 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item